June 22, 2017 / 9:40 PM / a month ago

BRIEF-FDA approves first subcutaneous C1 Esterase Inhibitor

1 Min Read

June 22 (Reuters) - U.S. Food and Drug Administration:

* FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease

* Granted approval of Haegarda to CSL Behring LLC

* Haegarda is a C1 Esterase Inhibitor for subcutaneous administration to prevent Hereditary Angioedema attacks in adolescent & adult patients

* Granted approval of Haegarda to CSL Behring LLC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below